hep C
Gilead to allow cheaper generics of new hep C drug
February 6, 2014Manufacturing and Production, Sales and Marketing Gilead, India, generics, hep C, s&m, sofosbuvir, sovaldi
Gilead has announced the unusual step of allowing its new and highly expensive hepatitis C pill to be sold as …
BMS revenue drops in 2013
January 27, 2014Sales and Marketing AZ, BMS, Yervoy, diabetes, hep C, q4
Bristol-Myers’ Squibb’s revenue has fallen 7% year-on-year to $16.4 billion during 2013. Turnover rose 6% to $4.4 billion in the …
Europe nod for Gilead HCV pill
January 20, 2014Sales and Marketing FDA, Gilead, HCV, hep C, sofosbuvir, sovaldi
Gilead Sciences’ once-daily, oral hepatitis C treatment Sovaldi has been given the green light by the European Commission, just a …
EMA to review daclatasvir
January 9, 2014Sales and Marketing BMS, EMA, daclatasvir, hep C
European regulators are to conduct a speedy investigation into one of Bristol-Myers Squibb’s investigational drugs for chronic hepatitis C virus …
AbbVie posts strong results for Hep C pill
December 11, 2013Research and Development, Sales and Marketing 3D, AbbVie, FDA, Gilead, hep C
AbbVie’s investigational hepatitis C pill cured 96% of difficult-to-treat patients in a late-stage clinical trial and looks set to muscle …
FDA approves Olysio
November 25, 2013Sales and Marketing FDA, Janseen, Janssen, hep C, hepc, olysio, simeprevir
US regulators have approved Janssen Pharmaceuticals’ Olysio, a new therapy to treat chronic hepatitis C virus infection, after a priority …
BMS abandons hep C, diabetes and neuroscience
November 11, 2013Sales and Marketing BMS, HIV, diabetes, hep C
Bristol-Myers Squibb is admitting defeat in hepatitis C, diabetes and neuroscience and will abandon research in these areas in a …
BMS files oral hep C treatment
November 5, 2013Sales and Marketing BMS, HCV, dvc, hep C
Bristol-Myers Squibb has filed its investigational hepatitis C treatment – the first oral regime without interferon or ribavirin – with …
‘Game-changing’ hep C pill gets FDA panel nod
October 29, 2013Sales and Marketing FDA, Gilead, hep C, sofosbuvir
Gilead Science’s investigational hepatitis C drug sofosbuvir is one step closer to approval in the US after an FDA advisory …
Janssen and GSK in hep C tie-ups
November 8, 2012Research and Development, Sales and Marketing GSK, Janssen, Vertex, hep C
Janssen and GlaxoSmithKline are to conduct separate Phase II studies with Vertex Pharmaceuticals to test an investigational all-oral regimen to …
Vertex abandons hep C drug
September 27, 2012Research and Development, Sales and Marketing Alios BioPharma, Vertex, hep C
Vertex Pharmaceutical’s pipeline has been dealt a blow with the abandonment of an investigational hepatitis C compound. The US firm, …
Two new hep C pills recommended by NICE
April 25, 2012Sales and Marketing Incivo, Janssen, MSD, NICE, Victrelis, hep C
NICE has given its final recommendation for two new hepatitis C pills in an expedited review. Janssen’s Incivo (telaprevir) and …
Janssen launches hep C support programme
February 27, 2012Medical Communications, Sales and Marketing BUPA, Copegas, Incivo, Janssen, Pegasys, hep C
Janssen has launched a hepatitis C support programme for patients in the UK to help with medicine adherence and healthy …
BMS to buy hep C firm Inhibitex for $2.5 billion
January 9, 2012Research and Development, Sales and Marketing BMS, Inhibitex, hep C
Bristol-Myers Squibb will acquire virology specialist Inhibitex for $2.5 billion, expanding its infectious disease portfolio. Bristol-Myers Squibb will acquire the …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
